Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia by Line of Therapy in the United States (US) from a Commercial Perspective

被引：0
作者：
Atallah, Ehab [1 ]
Maegawa, Rodrigo [2 ]
Latremouille-Viau, Dominick [3 ]
Rossi, Carmine [3 ]
Guerin, Annie [3 ]
Patwardhan, Pallavi [2 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
CML; chronic myeloid leukemia; chronic phase; tyrosine kinase inhibitors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-311
引用
收藏
页码：S333 / S333
页数：1
相关论文
共 32 条
  • [21] Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
    Atallah, Ehab L.
    Sadek, Islam
    Wei, David
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Damon, Andrea
    Yang, Daisy
    Bellefleur, Remi
    Guerin, Annie
    Jadhav, Kejal
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S365
  • [22] Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches
    Lipton, Jeffrey H.
    [J]. CLINICAL DRUG INVESTIGATION, 2024, 44 (02) : 91 - 108
  • [23] Real-world Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States
    Henk, Henry J.
    Woloj, Mabel
    Shapiro, Mark
    Whiteley, Jennifer
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (01) : 124 - 133
  • [24] Incidence of Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated with First-Line (1L) Tyrosine Kinase Inhibitors (TKI) in SIMPLICITY: An Observational Study
    Goldberg, Stuart L.
    Mauro, Michael
    Cortes, Jorge
    Keating, Scott J.
    Bhandari, Hitesh
    Chen, Clara
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S241 - S242
  • [25] Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
    Abou Dalle, Iman
    Kantarjian, Hagop
    Burger, Jan
    Estrov, Zeev
    Ohanian, Maro
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Cortes, Jorge
    [J]. CANCER MEDICINE, 2019, 8 (15): : 6559 - 6565
  • [26] Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs
    Ward, Melea A.
    Fang, Gang
    Richards, Kristy L.
    Walko, Christine M.
    Earnshaw, Stephanie R.
    Happe, Laura E.
    Blalock, Susan J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (02) : 289 - 297
  • [27] Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy
    Dongho Kim
    Hyun-Gyung Goh
    Soo-Hyun Kim
    Byung-Sik Cho
    Dong-Wook Kim
    [J]. International Journal of Hematology, 2011, 94 : 361 - 371
  • [28] Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States
    Atallah, Ehab L.
    Wei, David
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Damon, Andrea
    Ferreira, Germano
    Guerin, Annie
    Jadhav, Kejal
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (03) : 178 - 187.e2
  • [29] Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
    Smith, B. Douglas
    Cortes, Jorge E.
    Rea, Delphine
    Mauro, Michael J.
    Patwardhan, Pallavi
    Maegawa, Rodrigo
    Zacker, Christopher
    Corbin, Regina
    Keeping, Sam
    Sasaki, Koji
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S334
  • [30] Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI
    Ma, Chen-En
    Ghosh, Sunita
    Leyshon, Catherine
    Blosser, Nikki
    Dersch-Mills, Deonne
    Jupp, Jennifer
    Savoie, Lynn
    Liew, Elena
    Jamani, Kareem
    [J]. LEUKEMIA RESEARCH, 2021, 111
1234